Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Rebound in Shares of Applied Optoelectronics Inc Is Hardly Assured

By Chris Lau, InvestorPlace Contributor

Applied Optoelectronics looks like it has deep value at these levels, but investors should assess AAOI stock's risks.

Here’s What to Expect With Valeant Pharmaceuticals Intl Inc Q3 Results

By Chris Lau, InvestorPlace Contributor

Valeant's pared debt and sold assets. Even a small earnings beat or stronger outlook next month could send VRX stock sharply higher.

It’s Time to Forget About Alibaba Group and Start Giving JD.Com Inc(ADR) Some Attention

By Chris Lau, InvestorPlace Contributor

JD.com has growth potential in the luxury goods market. Recent acquisitions, investments and marketing initiatives will pay off for JD stock.

Why Micron Technology, Inc. Is Poised to Climb to $45 a Share

By Chris Lau, InvestorPlace Contributor

Micron is increasing revenue, and MU stock is poised to move higher, as we're in the middle of a super cycle in computer chips.

Rumors of Model 3 Production Constraints Should Unnerve Tesla Inc Shareholders

By Chris Lau, InvestorPlace Contributor

TSLA stock shareholders need to price in a slow ramp-up of Tesla Model 3 EVs, given the already-high expectations.

Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

By Chris Lau, InvestorPlace Contributor

Gilead Sciences’ Kite pharma deal is a good move while the underlying business in Hepatitis and HIV grows in 2018.

Get Rid of the Rotten Apple (AAPL), Invest in International Business Machines (IBM) Stock Instead

By Chris Lau, InvestorPlace Contributor

While Apple Inc. (AAPL) stock is trading close to yearly highs, International Business Machines Corp. (IBM) stock is nearing yearly lows.

Ambarella, Inc. (AMBA) Stock: Why Investors are Bidding Up the Shares

By Chris Lau, InvestorPlace Contributor

Ambarella stands ready to play big in the autonomous driving segment. That will be a big driver for AMBA stock.

Alibaba Group Holding Ltd (BABA) Stock Has New Highs Ahead, Thanks to Cloud and Mobile Taobao

By Chris Lau, InvestorPlace Contributor

With stock markets making new highs daily, Alibaba's (BABA) likely to reward investors. Alibaba Cloud and Mobile Taobao are two bright spots.

How Amazon.com, Inc (AMZN) Stock Can See $1,000 Again

By Chris Lau, InvestorPlace Contributor

Amazon.com (AMZN) is a super-expensive stock but it disrupts every business that it enters. That may be enough to satisfy bullish investors.

Load More